GABAergic neurotransmission and new strategies of neuromodulation to compensate synaptic dysfunction in early stages of Alzheimerâ€™s disease by Mauricio O. Nava-Mesa et al.
REVIEW ARTICLE
published: 25 June 2014
doi: 10.3389/fncel.2014.00167
GABAergic neurotransmission and new strategies of
neuromodulation to compensate synaptic dysfunction in
early stages of Alzheimer’s disease
Mauricio O. Nava-Mesa1*, Lydia Jiménez-Díaz 2 , JavierYajeya3, and Juan D. Navarro-Lopez2*
1 Neuroscience Research Group, University of Rosario, Bogotá, Colombia
2 Neurophysiology and Behavior Lab, Centro Regional de Investigaciones Biomédicas, School of Medicine of Ciudad Real, University of Castilla-La Mancha,
Ciudad Real, Spain
3 Department of Physiology and Pharmacology, University of Salamanca, Salamanca, Spain
Edited by:
Ludovic Martin, Université de Nantes,
France
Reviewed by:
Alexander Dityatev, German Center
for Neurodegenerative Diseases,
Germany
Jacques Epelbaum, Institut National
de la Santé et de la Recherche
Médicale, France




Neurophysiology and Behavior Lab,
Centro Regional de Investigaciones
Biomédicas, School of Medicine of
Ciudad Real, University of Castilla-La





School of Medicine, University of
Rosario, Kra 24 # 63C-69, Bogotá,
Colombia
e-mail: monavam@usal.es
Alzheimer’s disease (AD) is a progressive neurodegenerative disease characterized by
cognitive decline, brain atrophy due to neuronal and synapse loss, and formation of
two pathological lesions: extracellular amyloid plaques, composed largely of amyloid-
beta peptide (Aβ), and neuroﬁbrillary tangles formed by intracellular aggregates of
hyperphosphorylated tau protein. Lesionsmainly accumulate in brain regions thatmodulate
cognitive functions such as the hippocampus, septum or amygdala. These brain structures
have dense reciprocal glutamatergic, cholinergic, and GABAergic connections and their
relationships directly affect learning and memory processes, so they have been proposed
as highly susceptible regions to suffer damage by Aβ during AD course. Last ﬁndings
support the emerging concept that soluble Aβ peptides, inducing an initial stage of
synaptic dysfunction which probably starts 20–30 years before the clinical onset of AD, can
perturb the excitatory–inhibitory balance of neural circuitries. In turn, neurotransmission
imbalance will result in altered network activity that might be responsible of cognitive
deﬁcits in AD. Therefore, Aβ interactions on neurotransmission systems in memory-
related brain regions such as amygdaloid complex, medial septum or hippocampus are
critical in cognitive functions and appear as a pivotal target for drug design to improve
learning and dysfunctions that manifest with age. Since treatments based on glutamatergic
and cholinergic pharmacology in AD have shown limited success, therapies combining
modulators of different neurotransmission systems including recent ﬁndings regarding
the GABAergic system, emerge as a more useful tool for the treatment, and overall
prevention, of this dementia. In this review, focused on inhibitory systems, we will analyze
pharmacological strategies to compensate neurotransmission imbalance that might be
considered as potential therapeutic interventions in AD.
Keywords: septohippocampal system, amyloid-β peptide, excitatory and inhibitory neurotransmission, learning
and memory, Alzheimer’s disease
INTRODUCTION
Along last three decades, dementias are becoming a worldwide
epidemiological problem. The importance of understanding the
molecular basis of dementias and designing rational therapies
for its treatment is of growing interest for populations where
life expectancy along with concerns for a better quality of life
are increasing. In December 2005, it was estimated that there
were 24.3 million people living with dementia, there would be
31 million in 2010, and people affected by dementia will dou-
ble every 20 years, rising to 81.1 million in 2040. But the reality
is even worse than those approximations. People with demen-
tia need a great amount of support and care that imply a high
cost in terms of emotional, social, and ﬁnancial resources that
are mainly provided by their families with the help of local gov-
ernments or insurance companies. Being ailments that run over
a signiﬁcant time period, the direct and indirect cost of medical
care, employment of domestic caregivers, lost productivity in the
immediate family, etc., is enormous. A joint effort from researches
and health authorities needs to be made to deepen understanding
of the etiology and physiopathology of these diseases and therefore
develop therapies that improve health and welfare of people with
dementia.
Alzheimer’s disease (AD) is the most prevalent cause of demen-
tia among more than a hundred dementia types, and is the
major cause of dementia in the elderly (around 50% for age
range of 80–89 years old). According to the World Alzheimer
Report 2010–2012 (Alzheimer’s Disease International), in 2010
there were about 36 million cases of AD and other dementias
in the world, which will increase to 115.4 million in 2050. AD
is a devastating progressive neurodegenerative disease character-
ized by cognitive decline, brain atrophy due to neuronal and
synapse loss, and two neuropathological lesions ﬁrstly described
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by Alois Alzheimer in 1907: extracellular amyloid plaques and
neuroﬁbrillary tangles formation, composed of amyloid-beta
peptide (Aβ) and intracellular aggregates of hyperphosphory-
lated tau protein, respectively (Goedert and Spillantini, 2006).
Together with Parkinson’s disease, Huntington’s disease, trans-
missible spongiform encephalopathies and amyotrophic lateral
sclerosis, AD is one of the neurodegenerative diseases that presents
a pathological common mechanism (Soto, 2003) consistent on
conformational disorders of a particular protein which can fold
into a stable alternative conformation. In most cases, this alter-
ation results in its aggregation and accumulation in tissues as
ﬁbrillar deposits that ﬁnally induce neuronal death (Bucciantini
et al., 2002).
The events that trigger the main pathological changes in
AD take place in regions of the temporal lobe, including the
medial septum, hippocampus, amygdala, and entorhinal cor-
tex. The early onset of AD is manifested as an inability to form
new memories. However, the multiple structural and biochem-
ical changes which are already documented in the mid-to-late
stages of AD (such as synapse loss, plaque accumulation, tangle
formation, and neurodegeneration) do not explain the mem-
ory deﬁcits observed in the early stages of the illness (Selkoe,
2002). For example, the loss of synapses appears to be the
best morphological correlate for functional deﬁcits observed
in the middle and late stages of AD, but many patients in
early stages do not show a signiﬁcant decline in number of
synapses (Terry, 2004; Kelly et al., 2005; Spires-Jones and Knafo,
2012).
Based on these ﬁndings, attempts have been made to ﬁnd an
explanation for cognitive deﬁcits observed at early stages of the dis-
ease when no signiﬁcant decline in the synapse and cell number
has been detected. It has been proposed that misfolded oligomeric
forms or small Aβ aggregates that are not deposited in the tissue
might induce an initial state of synaptic dysfunction in early AD
patients. Numerous genetic, biochemical, and animal model stud-
ies have implicated the gradual contribution of Aβ, as a medium
for AD. In this sense, it has also been suggested that insoluble amy-
loid plaques would also have a pathogenic role serving as relatively
inert reservoirs of soluble toxic Aβ aggregates that could read-
ily be activated and disassembled by exposure to biological lipids
(Martins et al., 2008). This synaptic dysfunction scenario could
explain the cognitive deﬁcits observed in the early stages of ADand,
thus, precede synapse loss, plaque accumulation, tangle formation,
and neurodegeneration (Klein, 2002; Selkoe, 2002; Soto, 2003).
However, the mechanisms underlying functional deﬁcits are not
known yet.
During the last decade it has been suggested that an imbal-
ance between excitatory and inhibitory neurotransmission systems
might underlie the synaptic dysfunction caused by Aβ (Palop
et al., 2007; Sun et al., 2009; Palop and Mucke, 2010a; Verret et al.,
2012). Pharmacological treatments based on modulating excita-
tory and/or inhibitory neurotransmission have shown to improve
AD symptoms (Farlow, 2009; McKeage, 2009), so that strategies
aimed to reestablish the balance between both systems, particu-
larly in early stages of the disease, seem to be the most appropriate
to act on the functional deﬁcits caused by Aβ (Huang and Mucke,
2012; Mucke and Selkoe, 2012; Verret et al., 2012).
In this regard, the present paper will review the state of the
art of Aβ interactions on excitatory and mainly inhibitory neuro-
transmission inmemory-related brain systems such as amygdaloid
complex and septohippocampal system. These regions have shown
to be critical in cognitive functions and their neurotransmission
systems, particularly the inhibitory one, emerge as pivotal targets
for drugdesign studies to improve learning processes and cognitive
dysfunctions that manifest with age.
Aβ AND EXCITATORY NEUROTRANSMISSION
Several hypotheses have been postulated to explain the neuro-
toxicity of soluble Aβ aggregates on excitatory neurotransmission
systems. Some of these proposals include a cascade of reactions
that could involve the blockade of the glutamate recruitment
by microglia (Hickman et al., 2008), alteration of the gluta-
matergic neurotransmission (Ashenaﬁ et al., 2005; Santos-Torres
et al., 2007), or modiﬁcation of both glutamate N-methyl-
D-aspartate (NMDA) and/or α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid/Kainate (AMPA/Kainate) receptors endo-
cytosis process (Hsieh et al., 2006; Uemura et al., 2007). Other
authors consider intracellular calcium increase as the neurotoxic
mechanism (Rovira et al., 2002; Resende et al., 2007). Data from
Gu et al. (2003) support the cholinergic AD theory and therefore
affectation of muscarinic receptors (Kar et al., 1996), suggest-
ing alterations of potassium channels as Aβ action mechanism
(Zhang and Yang, 2006). None of these possible mechanisms have
completely been discarded at the moment.
The hypothesis explaining Aβ neurotoxic effects through
actions on glutamatergic receptors have received important sup-
ports. Neuroprotection against Aβ toxic effects has been described
by NMDA receptor blockade with MK801. This result supports
the idea that a persistent hyperpolarization can reduce the Aβ
neurotoxicity due to inactivation of NMDA receptors (Harkany
et al., 1999). In accordance, reduction of clinical deterioration in
the initial AD phases has also been described using the NMDA
glutamatergic non-competitive antagonistmemantine (O’Mahony
et al., 1998). Depression of glutamatergic response by Aβ perfu-
sion has been reported using electrophysiological recordings in
amygdala and septum (Ashenaﬁ et al., 2005; Santos-Torres et al.,
2007). Other authors support that Aβ alters glutamatergic trans-
mission affecting both metabotropic (Shankar et al., 2008; Um
et al., 2013) or AMPA/Kainate receptors endocytosis (Hsieh et al.,
2006). It has also been proposed that Aβ effect would be mediated
by increased NMDA receptors endocytosis (Uemura et al., 2007)
and other authors even postulate that Aβ acting on metabotropic
receptors (mGluRI) interferes with the regulation of GABAergic
transmission (Tyszkiewicz and Yan, 2005).
On the other hand, results supporting the cholinergic theory to
explain the mechanisms that underlie AD have also been shown
by many authors (Langmead et al., 2008). Muscarinic receptors,
speciﬁcally M1 subtype, have been broadly related to AD. M1 sub-
type receptor is widely distributed in the brain and is expressed
postsynaptically in cortex and hippocampus (Levey et al., 1991,
1995), important areas for learning and memory. In vitro studies
have demonstrated that activation of muscarinic receptors induces
an alternative pathway for amyloid precursor protein (APP) pro-
cessing which increases secretion of APP soluble fraction and then
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reduces Aβ toxicity (Fisher et al., 2002). In particular, selective
M1 agonist, AF267B, attenuates the major hallmarks of AD and
reverses deﬁcits in cognition (Caccamo et al., 2006, 2009). How-
ever, recent results suggest that a decrease in IM (the potassium
current activated by muscarinic receptor stimulation) may be an
integral part of AD pathophysiology (Leao et al., 2012; Duran-
Gonzalez et al., 2013), explaining why IM blockers fail to improve
cognition in AD clinical trials (Rockwood et al., 1997). Evidence
also points out that the initial injurious effects of the fragment
of Aβ, Aβ1−42, on M1 muscarinic receptor-mediated transmis-
sion is due to compromised coupling of the receptor with Gq/11
G-protein (Janickova et al., 2013). Nicotinergic neurotransmis-
sion has also been involved in AD early stages, not only through
an activation of presynaptic α7-nicotinic acetylcholine receptors
(α7-nAChR; Dougherty et al., 2003) but also by interaction with
GABAergic (Spencer et al., 2006) and glutamatergic (Wang et al.,
2009) systems.
Then in synaptic dysfunction processes, Aβ has been found
to present differential effects on AMPA and NMDA receptors.
NMDA has been related to Aβ neurotoxicity phenomena. How-
ever, cholinergic disruption induced by Aβ can be established at
different levels, including cholinergic neurodegeneration, alter-
ations in acetylcholine release, direct modulation of muscarinic
receptors and associated effectors, or nicotinergic system.
GLIAL CELLS IN THE PHYSIOPATHOLOGY OF AD
Recent reports support the new concept that cognitive function
arises from a cooperative activity between both neurons and glia
(Perea et al., 2009; Fields et al., 2014). This neuron–glia network
integrates information and controls synaptic transmission and
plasticity in an active way. The term “tripartite synapse” was
proposed in order to describe this cellular conﬁguration which
involves presynaptic neuron, postsynaptic neuron, and astrocytes
(Araque et al., 1999; Perea et al., 2009). Astrocyte-induced neuro-
modulation has been described in particular brain structures such
as hippocampus (Araque et al., 1998; Jourdain et al., 2007), cor-
tex (Ding et al., 2007), and hypothalamus (Gordon et al., 2005).
Several gliotransmitters released from astrocytes modulate synap-
tic plasticity in those brain structures (Yang et al., 2003; Pascual
et al., 2005; Panatier et al., 2006) and participate in learning and
memory processes.
Disruption of astrocytic functions and therefore in gliotrans-
mission may underline several brain disorders (i.e., depression,
schizophrenia, and epilepsy; Rajkowska et al., 1999; Cohen-Gadol
et al., 2004; Fellin et al., 2004; Webster et al., 2005), as well as
speciﬁc neurodegenerative diseases (i.e., parkinsonism; Forman
et al., 2005; Halassa et al., 2007). In fact, enhanced astrocytic
tau expression in aged transgenic animals results in glutamate-
transporter activity reduction and consequent neurodegeneration
(Komori, 1999; Dabir et al., 2004). In the context of AD, Aβ can
disrupt both astrocytic calcium signaling and glutamate uptake
capacity (Vincent et al., 2010; Matos et al., 2012). It has been
recently shown in an ex vivo astrocyte preparation, that Aβ1−42
reduces the expression of the two major glutamate transporters
in astroglia, GLT-1 and GLAST, through Adenosine A2A recep-
tors (de Vivo et al., 2010; Matos et al., 2012). Taking into account
that glutamate transporters are necessary for the clearance of
excitatory neurotransmitters, the resulting excitotoxic neuronal
damage induced by higher levels of Aβ through this mechanism
is reasonable in AD. On the other hand, the neuromodulatory
function of astrocytes in particular brain structures may explain
speciﬁc vulnerability to excitotoxicity and neurodegeneration.
Aβ pathological increases induce multiple glial morphological
changes. In fact, astrocytes and microglia become activated close
to senile plaques in order to internalize and degradeAβ (Mohamed
and Posse de, 2011). Oxidative stress and inﬂammatory response
inducedby astrocytes andmicroglia activationmayhave adual role
in pathophysiology of AD with neuroprotective and detrimental
consequences (Maccioni et al., 2001; Schipper et al., 2006). This is
the basis of the therapeutic use of non-steroidal anti-inﬂammatory
drugs (NSAID) in order to delay AD onset, as well as to reduce the
rate of disease progression (Cudaback et al., 2014). Unfortunately,
no clinical trials are available to support and recommend its use to
prevent AD. However, a novel compound (CHF5074) with both
anti-inﬂammatory and gamma-secretase (an enzyme involved in
APP processing) modulatory activities in animal models may have
a possible therapeutic role to prevent AD (Calza et al., 2013).
As mentioned previously, AMPA and NMDA receptors have
been widely implicated in the physiopathology of AD (for
review Parameshwaran et al., 2008). Several studies reported that
astrocytes express functional NMDA receptors (Kommers et al.,
2002; Lalo et al., 2006; Verkhratsky and Kirchhoff, 2007) which
are involved in neuronal–glial signaling, synaptic transmission
and cerebral vasodilation (Lalo et al., 2006; Palygin et al., 2010;
Parfenova et al., 2012). Therefore, Aβ-induced dysfunction of glu-
tamate receptors might affect NMDA receptors expressed in glial
cells and, as a consequence, disrupt neuron–glial signal transmis-
sion (Mota et al., 2014). NMDA receptor antagonists, MK801 and
memantine, might attenuate glutamate mediated cell excitotox-
icity by excessive stimulation of NMDA receptors in astrocytes
and neurons (Lee et al., 2010). In addition, regarding differences
between glial and neuronal NMDA receptors, a new selective
antagonist (UBP141) of astroglial NMDA receptors with potential
therapeutic role in neurodegenerative diseases has been developed
(Palygin et al., 2011). Finally, Talantova et al. (2013) showed that
Aβ was able to induce astrocytic glutamate release which led to
extrasynaptic NMDA receptor activation. In this case, nitrome-
mantine, improved NMDA receptor antagonist which selectively
inhibits extrasynaptic over physiological synaptic NMDA recep-
tors activity,may protect against Aβ-induced synaptic dysfunction
in hippocampus through selective extrasynaptic NMDA receptors
blocking. In addition, Aβ has been shown to disrupt glio-
transmission by enhancing calcium signaling through astrocytic
α7-nAChRswhich could aswell underlie glial-basedADpathology
(Lee et al., 2014).
Thus, devolvement of novel drugs targeting glial signaling may
have a possible therapeutic role in AD. In fact, antiepileptic drugs
such as levetiracetam reversed synaptic dysfunction and learn-
ing and memory deﬁcits in human APP (hAPP) transgenic mice
(Sanchez et al., 2012). One of the action mechanisms of levetirac-
etam is glutamate and GABA transporters increase in neurons
and astrocytes (Ueda et al., 2007). Reduction in glutamate excito-
toxicity and enhancement of inhibitory neurotransmission after
chronic levetiracetam administration demonstrates a molecular
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mechanism which involves glial cells, to attenuate cognitive
abnormalities in AD.
Finally, astrocytes and neurons work together through sev-
eral metabolic pathways in order to perform new synthesis of
glutamate and GABA (Bak et al., 2006). At inhibitory synapses
this pathway is called the GABA–glutamine cycle and it depends
on GABA transporters and a multi-enzyme machinery that coor-
dinates this process (i.e., GABA transaminase, glutamate decar-
boxylase, and glutamine synthetase; Bak et al., 2006; Hertz, 2013).
Several studies indicate that the activity of glutamine synthetase
is decreased in AD. Dysfunction of astrocyte metabolism and
therefore glutamate and GABA–glutamine cycles may underlie
cognitive impairment in AD (Le Prince et al., 1995; Robinson,
2000; Nilsen et al., 2014). Drugs targeting GABA-metabolizing
enzyme and neurotransmitter transporters are of therapeuti-
cal interest in GABA-related neurological disorders (Sarup et al.,
2003). However, taking into account the different functional roles
of glial and neuronal neurotransmitter transporters and the over-
lapping in GABA/glutamate metabolic pathways, developing of
high selective cell-speciﬁc drugs is necessary in order to avoid
pharmacological interactions and unpredictable side effects.
In summary, glial cells are dramatically affected in AD. Aβ-
induced dysfunction of glutamate receptors (NMDA) in astrocytes
disrupts neuron–glial signal transmission. On the other hand, Aβ
interaction with cholinergic receptors (i.e., α7-nAChR) and glu-
tamate transporters in glial cells may explain neurotoxicity and
selective neurodegeneration. Reducing the activation of astro-
cytes and microglia is the basis of anti-inﬂammatory drugs in AD.
Finally,metabolism and new synthesis of GABA in glial cells might
be an interesting target to selective pharmacological modulation.
Aβ AND EXCITATORY NEUROTRANSMISSION: AMYGDALOID COMPLEX
Amyloid depositions are found not only in the hippocampus but
in other subcortical brain structures. In fact, brain amyloidosis in
subjects with higher vulnerability to AD pathology (i.e., individ-
uals with mild cognitive impairment, MCI) includes structures
such as parietal association cortices, posterior cingulate, pre-
cuneus, amygdale, and caudate (Tosun et al., 2013). Among these
brain regions, the number of senile plaques has been reported to
be the highest in amygdala (Arriagada et al., 1992). Accordingly,
a recent diffusion-tensor imaging study has revealed signiﬁcant
decrease in the relative volume of amygdale in early stage AD
subjects (Li et al., 2013). The amygdala has long been known to
be vulnerable to Alzheimer-type pathology (Hopper and Vogel,
1976), and it has been described as one of earliest locations to
develop Alzheimer pathology in Down syndrome (Mann et al.,
1986). AD subjects develop brain pathology similar to that of
Down syndrome, including Aβ depositions (Nardone et al., 2006).
Asymmetrical neuronal loss in the amygdala ranges from 35% to
70% in AD (Scott et al., 1992; Vereecken et al., 1994). In addition,
it has been reported that neuronal loss was more severe in the cor-
ticomedial regions than in the basolateral region of the amygdala
(Tsuchiya and Kosaka, 1990). The distribution pattern of neu-
ronal loss was similar to that of neuroﬁbrillary tangles instead of
the distribution of senile plaques (Tsuchiya and Kosaka, 1990).
Severity of amygdala pathology correlates with disease duration
in AD (Arriagada et al., 1992), and amygdala pathology has been
associated with emotional and memory disturbances (Zald, 2003).
Despite the importance that amygdaloid complex seems to have,
few studies have investigated how Aβ induces injury and may con-
tribute tounderlie the emotional and cognitive symptoms typically
observed in AD patients.
Based on the amygdala’s cytoarchitecture its subnuclei can be
classiﬁed in superﬁcial amygdaloid nuclei, centromedial group,
and the basolateral complex (Heimer et al., 1999; Amunts et al.,
2005). The basolateral amygdaloid complex is formed by the lat-
eral, basolateral, and basomedial nuclei (Swanson and Petrovich,
1998), and innervated by cortical projections across the external
capsule. In the amygdala, the excitatory synaptic activity evoked
by stimulation of the external capsule is fundamentally mediated
through the action of glutamic acid onAMPA/Kainate andNMDA
receptors (Rainnie et al., 1991; Smith and Dudek, 1996). The
amplitude of these responses is signiﬁcantly depressed byAβwith-
out changes in membrane resistance values, which conﬁrms that
Aβ effect is localized at synaptic level (Ashenaﬁ et al., 2005). Specif-
ically, the Aβ effect seems to be located at presynaptic level since
it could be prevented by calcicludine or nifedipine, both selec-
tive antagonists of presynaptic L-type calcium channels (Ashenaﬁ
et al., 2005).
Regarding cholinergic neurotransmission, the magnocellular
division of the basal nucleus presents a high density of acetyl-
cholinesterase positive ﬁbers (Amaral and Bassett, 1989). The
activation of these ﬁbers generates depolarization of long duration
in pyramidal cells, which is blocked by atropine (a competi-
tive muscarinic receptor antagonist; Washburn and Moises, 1992;
Moises et al., 1995). Muscarinic agonists, such as carbachol,mimic
this type of response in the amygdaloid pyramidal neurons
(Washburn and Moises, 1992; Yajeya et al., 2000). This effect is
mediated by the closure of potassium channels and/or opening
of non-speciﬁc cationic channels (Yajeya et al., 1997, 1999, 2000).
On the other hand, data from Wang et al. (2000) showed that
Aβ1−42 mayblock presynapticα7-nAChR inneurons derived from
human brain tissues and neuroblastoma cells. It can be assumed
that as a consequence of such blocking, the concentration of cal-
cium in the synaptic terminal diminishes, producing a decrease in
the amount of neurotransmitter releasedwhen the terminal is acti-
vated. Although the existence of these receptors has been veriﬁed in
presynaptic terminals of the amygdala (Girod et al., 2000), a previ-
ous study in our grouphas shown thatα7-nAChRwas not involved
in the Aβ25−35 short-term neuromodulatory effects in basolateral
amygdaloid complex (Ashenaﬁ et al., 2005). In addition, nico-
tine stimulates mRNA expression of APP in the amygdala (Gutala
et al., 2006). However, its functional implications in amygdaloid
complex have not been deeply studied.
Aβ AND EXCITATORY NEUROTRANSMISSION: SEPTOHIPPOCAMPAL
SYSTEM
Septum and hippocampus are structures dense and reciprocally
interconnected through ﬁmbria–fornix complex, and are func-
tionally coupled to form the septohippocampal system, which
shows a critical involvement in generating certain oscillatory activ-
ity, such as theta rhythm, necessary for fundamental processes in
learning and memory (Stewart and Fox, 1990; Bland and Oddie,
2001; Buzsaki, 2002; Sotty et al., 2003; Colom, 2006; Colom et al.,
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2010; Rubio et al., 2012). Theta oscillation coordinates septo-
hippocampal network and depends on interconnections, which
include well known cholinergic and GABAergic components
(Lynch et al., 1977; Kohler et al., 1984; Bland andColom,1993) and
recently described glutamatergic projections (Sotty et al., 2003;
Huh et al., 2010).
The initial symptoms of AD involve memory impairment
and disorientation (McKhann et al., 1984; Swanberg et al., 2004).
Damages found in septum and hippocampus could explain
those cognitive deﬁcits (Moreno et al., 2007; Palop et al., 2007;
Villette et al., 2010; Rubio et al., 2012). Functional images applied
in AD subjects have detected defects in the hippocampal forma-
tion, a brain structure where the disease begins (Bland and Colom,
1993; Gonzalez et al., 1995; Harris et al., 1998; Wu and Small,
2006). It has been shown that cholinergic cells of the medial
septum/diagonal band of Broca (MS–DBB) and the enzymes
necessary for the synthesis of acetylcholine, are particularly sus-
ceptible to disturbance, with consequent dysfunction in cognitive
processes (Yamaguchi and Kawashima, 2001). Intracerebroven-
tricular (i.c.v.) injection of Aβ25−35: (i) reduces the activity of
acetylcholinesterase in the medial septum, cortex, and hippocam-
pus of rats (Yamaguchi and Kawashima, 2001); (ii) decreases
performance in passive avoidance andwatermaze tests (well estab-
lished learning and memory tests); (iii) and also reduces neuronal
loss and appearance of Aβ deposits in cortex, hippocampus, and
caudate nucleus (Maurice et al., 1996). Moreover, the septal injec-
tion of different fragments of Aβ (Aβ18−28, Aβ25−35, or Aβ1−40)
produces a marked reduction in basal or induced release of acetyl-
choline (Kar et al., 1996). Inhibition of acetylcholine release is
also observed in the hippocampus and cortex in in vitro rat
brain slices using different Aβ fragments (Kar et al., 1996). It has
also been shown that Aβ inhibits some of the effects mediated
by acetylcholine through septohippocampal muscarinic receptors
(Kar et al., 1996; Santos-Torres et al., 2007). This capability could
contribute to the particular Aβ vulnerability of cholinergic neu-
ronal populations. However, the low concentrations (nanomolar)
with which such effects are obtained, along with the fact that
nervous system cells actively secrete Aβ product, suggest the pos-
sibility that this peptide may have physiological activity, acting as
a neuromodulator not only on the cholinergic, but also on other
neurotransmission systems.
In vitro studies in septum slices have found that Aβ induces a
deﬁcit in glutamatergic synaptic transmission (Santos-Torres et al.,
2007). It has recently been observed in vivo that septal glutamater-
gic neurons are vulnerable to Aβ through excitotoxic mechanisms
(Colom et al., 2010). The two characteristics of the theta rhythm,
frequency and amplitude, are affected by modulation of septal
NMDA receptors (Puma and Bizot, 1999; Bland et al., 2007). Fur-
thermore, injection of NMDA antagonists in MS–DBB decreases
the amplitude of hippocampal theta rhythm (Leung and Shen,
2004). This indicates that glutamatergic MS–DBB circuits are also
affected by Aβ and are important for the generation and mainte-
nance of septohippocampal rhythmic activity amplitude at theta
frequencies (Colom et al., 2010).
Aβ has also shown to induce dysfunction of septal glutamater-
gic neurons involvingmuscarinic receptor effectors, the potassium
voltage-gate channels, KCNQ (Leao et al., 2012). In this case, Aβ
diminishes septal rhythmicity by decreasing KCNQ conductance,
which negatively affects hippocampal rhythmogenesis and could
underlie thememory loss observed inAD(Leao et al., 2012). In this
sense, it has been reported that in the septohippocampal system
Aβ reduces not only KCNQ2 subunit expression and then, KCNQ
conductance, altering the neuronal excitability but also the expres-
sion of the oxidative stress-related genes superoxide dismutase 1
(SOD1), 8-oxoguanine DNA glycosylase (OGG1), and monamine
oxidase A (MAOA). This situation leads to a neuronal dysfunc-
tion and damage that could not be ﬁxed because of the decreased
expression of repairing genes (Duran-Gonzalez et al., 2013).
Recent studies have shown that Aβ binds to α7-nAChR in sev-
eral brain structures including the hippocampus (Spencer et al.,
2006; Soderman et al., 2008). On the other hand, it has been
proposed that α7-nAChR is functionally blocked in hippocam-
pal CA1 neurons due to an interaction between the receptor and
Aβ (Soderman et al., 2011). The functional consequences of such
interaction may lead to impairments in both cognitive function
(Soderman et al., 2008) and synaptic plasticity (Soderman et al.,
2011). α7-nAChR inhibition has also been explained by sustained
increase in presynaptic Ca2+ evoked by Aβ which may underlie
disruption of neuronal signaling via nAChRs in the early stages of
AD (Dougherty et al., 2003). Since nicotine is able to induce LTP
in CA1 hippocampal region probably due to reducing GABAergic
inhibition and therefore, increasing the excitability of pyramidal
neurons (Fujii et al., 2000), is plausible a functional interaction
between α7-nAChR and GABAergic system. However, hippocam-
pal GABAergic interneurons exposed to high levels of amyloid still
presented α7-nAChR-mediated activity (Spencer et al., 2006). On
the other hand, α7-nAChR and NMDA glutamatergic receptor
activities are impaired in synaptosomes derived from AD post-
mortem tissue and in presence of high Aβ1−42 levels (Wang et al.,
2000). Hence it will be essential to advance in the knowledge of
α7-nAChR as therapeutic target for the treatment of Aβ-induced
pathology and AD (Kem, 2000; Chen et al., 2006; Dziewczapolski
et al., 2009).
Aβ AND GABAergic NEUROTRANSMISSION
The regulation of many physiological and cognitive processes is
depends on a ﬁne tuning between excitatory and inhibitory sys-
tems. In order to maintain neural network stability, GABA, the
main inhibitory neurotransmitter in the mammalian central ner-
vous system (Cardinali andGolombek, 1998), is known to regulate
excitatory activity preventing neuronal hyperexcitation as well as
oscillatory activity and ﬁring rate impairments in neural networks
(Oren et al., 2006; Zemankovics et al., 2013).
GABAergic neurons are the principal inhibitory neurons and
one of the major local circuit neurons (Moore, 1993) which
has been implicated in the regulation of a variety of behav-
ioral functions such as learning and memory (Chapouthier, 1989;
Vinogradova et al., 1998). In fact, GABAergic inﬂuence is the key
to generate rhythmic synchronization of neurons during theta
and gamma activity in different brain regions, contributing to
neuronal communication and memory processing (Somogyi and
Klausberger, 2005; Gong et al., 2009). Cortical and hippocampal
function depends on optimum levels of inhibition (Borhegyi et al.,
2004; Kaifosh et al., 2013; Xu et al., 2013; Bissonette et al., 2014) to
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maintain an adequate synaptic plasticity activity. For a long time,
GABAergic neurotransmission has been considered well preserved
in AD (Rissman et al., 2007). However, cumulative evidence indi-
cates that changes in GABAergic neurotransmission are involved
in the physiopathology of AD and may be very important as a pos-
sible target to pharmacological intervention previous to cognitive
dysfunction in early AD. Below, we have reviewed the effect of Aβ
on inhibitory GABA system in the different brain structures which
relate to cognitive deﬁcits in AD.
It has been already discussed in this review that excitatory neu-
rotransmission contributes to the pathogenesis and progression of
AD and as a result could serve to disrupt the excitatory/inhibitory
balance in brain structures, participating in memory processing
and therefore taking part of mechanisms that could explain cog-
nitive dysfunction. It is important to consider that alterations
on inhibitory neurotransmission or GABA receptors may also
induce a signiﬁcant impact on brain structures and functions, and
might also participate in the dysregulation of the balance between
excitatory and inhibitory neurotransmission seen in AD patients
(Palop et al., 2007; Palop and Mucke, 2010b; Mucke and Selkoe,
2012). In fact, increased epileptiform activity and non-convulsive
seizure induced by Aβ in both, animals models of AD (Palop
et al., 2007) and AD in elderly people (Palop and Mucke, 2009,
2010a; De Simone et al., 2010) suggests that disruption of excitora-
tory/inhibitory balance by Aβ involves different neurotransmitter
systems including the GABAergic.
Cognitive deﬁcits inAD are explained by selective vulnerability,
neurodegeneration, and loss of function of neuronal popula-
tions and neurotransmitter systems in particular brain regions
such as hippocampus, septohippocampal system, and amygdala.
Acetylcholine-releasing neurons and glutamatergic neurons in
basal forebrain and hippocampus, respectively, are particularly
vulnerable to Aβ neurotoxic effects (Coyle et al., 1983; Emre
et al., 1992; Danysz et al., 2000; Giannakopoulos et al., 2009) while
GABAergic neurons are relatively resistant to neurodegeneration
in AD (Rissman et al., 2007). Recently, in a mouse model of
AD it has been shown that glutamatergic hippocampal terminals
decrease after Aβ1−42 perfusion while no signiﬁcant changes in
GABAergic terminals were observed (Canas et al., 2014). GABAer-
gic synapses are preserved in human AD and APP/PS1 transgenic
mice (Mitew et al., 2013). However, Aβ might have indirect
effects on the inhibitory GABAergic transmission as a result of
the dynamic GABAergic balance modulation of the other two
excitatory systems (cholinergic and glutamatergic neurotransmis-
sion). It has recently been suggested that the imbalance between
excitatory and inhibitory systems underlies the synaptic dysfunc-
tion caused by Aβ (Sun et al., 2009; Palop and Mucke, 2010a).
As a consequence of relative sparing of GABAA receptors in
AD, GABAergic sprouting in cortical and hippocampal networks
enhance synaptic inhibition in order to compensate aberrant
increases in network excitability (Palop et al., 2007). Hypersyn-
chronous neuronal activity on those networks and Aβ-induced
neurological deﬁcits before neurodegeneration can be explained
by this mechanism. Increase on glutamic acid decarboxylase
(GAD, the rate-limiting enzyme synthesizing GABA) activity and
consequently on the tone of the GABAergic system in AD brains
has also been reported (Reinikainen et al., 1988). According to
previous GABAergic hypothesis, this increase on extracellular
GABA levels leads to alterations in neuronal membrane func-
tions, abnormally enhanced synthesis of APP and facilitates
neurodegeneration in basal forebrain system (Marczynski, 1998).
Controversially, selective somatostatin/NPY inhibitory interneu-
rons neurodegeneration has been described in the hippocampus
of a transgenic presenilin 1 PS1/APPAD model, with preservation
of GABAergic mRNA synaptic markers (Ramos et al., 2006). In
the same animal model, hyperactive neurons in cortical circuits
are linked with a relative decrease in synaptic inhibition rather
than increase in excitatory glutamatergic neurotransmission, sug-
gesting impairments in GABAergic function (Busche et al., 2008;
Palop and Mucke, 2010a). A recent report also shows that in mice
expressing hAPP, the network dysfunction (hypersynchrony and
reduced gamma oscillatory activity) and memory deﬁcits in AD
might arise from inhibitory interneurondeﬁcit (Verret et al., 2012).
In line with the above scenario, therapies aimed at increasing
GABAergic activity may reduce network/synaptic dysfunction on
brain structures which participate in memory processing in AD
subjects. Besides potential beneﬁts of drugs which attenuate the
Aβ-induced synaptic dysfunction, several previous studies have
shown that selective GABAA receptor agonists (i.e., muscimol)
are able to protect against Aβ-induced neurotoxicity in retinal,
hippocampal, and cortical neurons in rodents (Gu et al., 2003;
Paula-Lima et al., 2003; Louzada et al., 2004; Lee et al., 2005).
Some neuroprotective effects of GABA modulators (i.e., Etazo-
late, selective GABAA receptor modulator) could be blocked by
GABAA receptor antagonists (Marcade et al., 2008), indicating that
these neuroprotective effects were due to GABAA receptor signal-
ing and opening new therapeutic possibilities for AD treatment
(Vandevrede et al., 2013). In fact, GABAA receptor agonists to
treat age-related cognitive deﬁcits were proposed as a new thera-
peutical approach in the 11th Alzheimer’s Disease Drug Discovery
International Conference (Wolfe, 2010a,b). However, none precise
action mechanism has been well described. Stimulation of GABA
receptors by pentobarbital apparently restores neuronal matura-
tion and neurogenesis in apolipoprotein E (APOE)4 knocking
mice (Li et al., 2009). Apolipoprotein E4 is considered as a major
genetic risk factor for early onset AD perhaps by accelerating Aβ
plaque formation, or by impairing neuron repair (Baum et al.,
2000; Lopez, 2011; Seppala et al., 2012). Despite the plausible neu-
roprotective effects of GABA agonists, the widely described side
effects limit its long-term use (Lanctot et al., 2004, 2007). Further-
more, there is evidence of long-term effects of benzodiazepines
(GABAA agonists) and their relationship with increased risk of
dementia (Gallacher et al., 2012).
Cerebrospinal GABA studies as well as neuroimaging and post-
mortem studies have been useful to show the relationship between
GABA system and AD (Jimenez-Jimenez et al., 1998; Yew et al.,
1999; Lanctot et al., 2004). Postmortem autoradiographics and
benzodiazepine binding studies of GABA receptors in cortex and
hippocampus have been controversial to demonstrate changes in
GABAA receptors levels; however, most of them have shown a rel-
ative decrease in GABAA receptors expression in frontal, temporal,
and parietal cortical regions and limbic structures. GABAA sub-
units speciﬁc susceptibility could explain those dissimilar results.
However, alteration in GABAA receptor subunits has shown
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paradoxical results probably due to compensatory mechanisms
which are not well described (Mizukami et al., 1997, 1998; Howell
et al., 2000; Rissman et al., 2003, 2007; Iwakiri et al., 2009). It is
plausible that some effects on GABA dysfunction in AD induced
by Aβ are not necessarily associated with a signiﬁcant damage on
GABA neurons or reduced expression of GABAA receptors, and
could be explainedby functionalGABAA receptor activity changes.
In fact, a conventional voltage-clamp study showed that Aβ may
increase neuronal excitability by inhibiting GABA-induced Cl−
current in the neurons of central nervous system (Sawada and
Ichinose, 1996). This result suggests that GABA modulators and
agonists can normalize Cl− ﬂux and possibly restore the func-
tional properties and excitability of theses neurons. In a series of
elegant studies, the microtransplantation of functional receptors
and channels from the humanAD brain to frog oocytes showed an
amplitude reduction of the currents elicited by GABA application,
indicating that receptor-channel function was impaired (Miledi
et al., 2004) or resulted from a diminished number of GABAA
receptors in the membranes of AD brains (Bernareggi et al., 2007).
Finally, GABA currents fromADbrains have a faster and less sensi-
tive rate of desensitization than those from control brains (Limon
et al., 2011), which was explained by down regulation of α1 and
γ2 receptor subunits while a compensatory up-regulation of α2,
β1, and γ1 receptor subunits took place. Selective pharmacological
modulators of GABAA subunits (i.e., α5-selective inverse agonist)
may be effective to increase cognitive performance in memory dis-
orders (Atack, 2010). Age-dependent reduction of GABA currents
in AD brain from human postmortem tissue indicates a reduc-
tion of principal GABA receptors subunits (Limon et al., 2012).
However, one of the major problems when GABAergic drugs are
chronically used is the desensitization. It has been suggested that
such phenomenon could be removed with phosphatase inhibitors
or neurotrophic factors which positively modulate GABA currents
(Palma et al., 2005; Limon et al., 2011) and both could be potential
therapeutic targets for new AD drugs.
Hence, although some AD models have shown that the
GABAergic system is relatively well preserved, Aβ might have
indirect effects on GABAergic neurotransmission and induce
inhibitory interneuron deﬁcits, which could underlie neuronal
hyperexcitability observed inAD.On the other hand, long-termAβ
exposition generates increased GABAergic activity and up/down
regulation of speciﬁc GABAA subunits, as a compensatory mech-
anism. The understanding of those acute and chronic differential
effects of Aβ on inhibitory systems is a pivotal point to develop
novel therapeutical strategies to reduce cognitive impairment in
early AD.
Aβ AND GABAergic NEUROTRANSMISSION: AMYGDALOID COMPLEX
Aspreviously discussed in this review, there is general agreement to
state that amygdala participates in emotional behavior processing.
Afferent and efferent speciﬁc connections of the amygdala with a
large variety of cortical and subcortical structures are the basis of
cognitive functions and affective behaviors such as stress, defense,
escape, pain, motivation, emotional discrimination, learning,
and memory (Swanson and Petrovich, 1998; LeDoux, 2000; Gill
and Grace, 2013). GABAergic afferents originating from amyg-
daloid interneurons of the basolateral complex which synapse on
pyramidal cells probably modulate its function (McDonald, 1985;
Carlsen, 1988; Carlsen and Heimer, 1988; McDonald and Augus-
tine, 1993). In fact, altered signaling in GABAergic systems in
amygdala produces impairments in emotional learning and mem-
ory tasks (Bolton et al., 2012). Regarding the above scenario, it has
been proposed that inhibitory GABAergic activity in the basolat-
eral amygdala cooperates to promote amygdala–hippocampal syn-
chrony involved in emotional memory formation (Bienvenu et al.,
2012). Amygdala dysfunction has been related to both AD (Bien-
venu et al., 2012) and Aβ pathology in rodents (Devi and Ohno,
2010; Huang et al., 2010). Previously, our group demonstrated that
GABAA inhibitory evoked responses decreased in amplitude after
Aβ perfusion in basolateral amygdaloid complex through a presy-
naptic mechanism (Ashenaﬁ et al., 2005). A transgenic mice study
has shown that accumulation of Aβ in GABA neurons of the baso-
lateral amygdaloid complex was related to enhanced innate and
conditioned fear symptoms and spatial memory deﬁcits (España
et al., 2010). These results suggest that Aβ-induced dysfunction
of GABAergic activity in key brain structures as amygdala might
explain the emotional symptoms in AD such as anxiety and fear,
as well as faster cognitive decline in memory processing.
A single neurotransmitter imbalance orAβ-induced neurotoxic
effects in a speciﬁc brain nucleus would not explain the pathol-
ogy which involves whole brain regions and circuits. However,
some psychological symptoms in AD subjects have been associ-
ated with GABAergic changes (Lanctot et al., 2007) and GABAA
agonists have been widely used in the treatment of some behav-
ioral and psychological symptoms of AD, such as aggression and
agitation (Lanctot et al., 2004). Aβ-induced changes in GABAergic
neurotransmitter system in amygdala would help us to under-
stand the pathophysiology mechanism of emotional symptoms in
AD subjects.
Aβ AND GABAergic NEUROTRANSMISSION: SEPTOHIPPOCAMPAL
SYSTEM
The function of septal neurons of the basal forebrain is to mod-
ulate hippocampus and neocortex circuits’ activity in order to
maintain sensory information and memory processes (Colom,
2006; Colom and Garrido-Sanabria, 2007). GABA neurons
have been well described in that region in close proximity to
cholinergic neurons in the MS–DBB complex (Kimura et al.,
1980; Castañeda et al., 2005). In the same complex, burst-ﬁring
GABAergic neurons contribute to hippocampal theta rhythm in
vivo (Sotty et al., 2003). Similarly, inhibitory neurons of themedial
septumprovide rhythmicdrive to thehippocampus independently
of intrahippocampal theta genesis (Hangya et al., 2009). GABA-
containing afferents originating in the septum innervate most of
the inhibitory interneurons in the hippocampus, which, in turn,
control the activity of large populations of excitatory pyramidal
cells (Freund andAntal, 1988). As a result, these septohippocampal
GABAergic projections have a main role in modulating electrical
rhythmic activity in the hippocampal formation.
In vivo experiments in rats have shown that cholinergic and
GABAergic neurons from medial septum are involved in gener-
ating theta rhythmicity in the hippocampus (Simon et al., 2006).
Predictive modeling of hippocampal microcircuits has shown that
inhibitory interneurons from septum have a main role in spatial
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memories as well as in the maintenance of theta phase precession
phenomenon of principal cells (Cutsuridis et al., 2010; Cutsuridis
and Hasselmo, 2012). Because theta and gamma activity play a
functional role in memory formation and retrieval (Bastiaansen
and Hagoort, 2003; Hasselmo, 2005; Lisman, 2005), disruption of
septohippocampal projection might explain cognitive deteriora-
tion in neurodegenerative diseases. Actually, several studies have
demonstrated the relationship between Aβ-induced pathology
and septohippocampal dysfunction as follows. In an interesting
study, after single injection of Aβ1−40 into the medial septum,
a signiﬁcant reduced hippocampal theta rhythm was reported,
associated with damage on cholinergic and glutamatergic neurons
activity controlled by the GABAergic system (Colom et al., 2010).
Similarly, Aβ1−42 injection into the MS–DBB complex preferen-
tially injures septal cholinergic neurons but not inhibitory cells
(Harkany et al., 1995). Despite these studies have proven that
septal GABAergic neurons are spared after acute Aβ injection
in septum, this consideration would not mean that Aβ induced
septohippocampal dysfunction is not associated with inhibitory
functional changes. By using in vivo preparations, it has been
proposed that reduction of septal cholinergic and glutamatergic
inputs onto GABAergic septal neurons may reduce the popula-
tion of rhythmically bursting GABAergic neurons and suggest
that GABAergic neurons are dysfunctional in Aβ-treated rats
(Colom et al., 2010). Similarly, hippocampal Aβ1−40/31−35 injec-
tions induce a signiﬁcant impairment of spatial memory in rats
and concomitant reduction in the hippocampal theta rhythm (Liu
et al., 2013). Aβ effects are associated with GABAergic neurons
dysfunction and greatly weakened septal theta transmission to the
hippocampus rather than interfere with its generation. Therefore,
hippocampal Aβ-induced pathology reduces the bursting activity
of septohippocampal GABAergic neurons (Villette et al., 2010).
As previously stated, these neurons contact with hippocampal
GABAergic interneurons, which in turn, control the pyramidal
neurons rhythm. Since GABAergic septohippocampal neurons
and hippocampal interneurons are relatively spared, these effects
are probably due to functional regulation changes rather than
neurodegeneration or reduction in GABA receptors expression.
Conversely, a study with a triple-transgenic mouse model
of AD (TauPS2APP) revealed a signiﬁcant neurodegeneration
of GABAergic septohippocampal projection neurons as well as
GABAergic hippocampal neurons (Loreth et al., 2012). Accord-
ingly, loss of GABAergic septohippocampal axon terminals in
the mouse model hAPP has been described (Rubio et al., 2012).
However, some of these changes are not caused by neuronal loss.
Recently, it has been reported in vivo that Aβ injection in dorsal
hippocampus induces a selective death of GABAergic neuronal
subpopulations projecting to the medial septum (Villette et al.,
2012). In this sense, even with differences in the currently avail-
able models of AD, GABAergic decline in the septohippocampal
projections may explain loss of hippocampus oscillatory activity
necessary for learning and memory processes.
Hippocampal theta and gamma rhythms changes occur dur-
ing the early stages of AD as a product of excitation–inhibition
imbalance (Goutagny and Krantic, 2013). As described above,
these changes may be related with Aβ effects on MS–DBB
and afferents which in turn modulate hippocampus activity.
However, hippocampal formation itself is a particularly vulner-
able region to Aβ peptide accumulation (Moreno et al., 2007;
Double et al., 2010). As a consequence, hippocampal atrophy and
neurodegeneration are common features found in AD (Hof and
Morrison, 1991; Cummings and Cole, 2002; Casas et al., 2004).
AcuteAβ rise induces neurotoxic damage and synaptic dysfunction
affectingGABAergic neurotransmitter system in the hippocampus
and associative cortex by numerous mechanisms, affecting their
function before neurodegeneration and accumulation of Aβ in
senile plaques occurs (Selkoe, 2002; Klingner et al., 2003). In fact,
cumulative evidence shows that soluble forms of Aβ can interfere
with hippocampal synaptic plasticity responsible for learning and
memory processing, inhibit long-term potentiation (LTP), and
enhance long-term depression (LTD; Chen et al., 2000; Freir et al.,
2001; Shankar et al., 2008; Ondrejcak et al., 2010). Hippocam-
pal LTP in an AD animal model, the transgenic APP/PS1 mice,
is larger after perfusion with GABAA receptor antagonist as a
product of changes in synaptic protein levels. These data suggest
that reduced LTP is associated to an enhanced GABAA receptor-
mediated inhibition (Fernandez et al., 2007; Yoshiike et al., 2008).
Several studies previously reported cognitive improvement in the
presence of chronic systemic treatment with GABAA antagonists
(i.e., ﬂumazenil or picrotoxin; Marczynski, 1995, 1998; Fernandez
et al., 2007; Yoshiike et al., 2008). According to these authors, those
blockers are plausible useful therapeutic agents for age-related loss
of cognitive functions in AD animal models. Nevertheless, other
studies afﬁrmed that Aβ-impairment effects on LTP appear to
be independent of GABAA receptor-mediated synaptic inhibition
because perfusion with picrotoxin had no effect on the inhibition
of LTP (Raymond et al., 2003). Additionally, GABAergic synaptic
transmission onto the hippocampus was affected by i.c.v. injec-
tion of Aβ1−40 and Aβ1−42 (Cullen et al., 1997) or Aβ25−35 (Sun
and Alkon, 2002). Finally, several studies have reported speciﬁc
GABAergic interneurons decrease (parvalbumin, calretinin, and
somatostatin/NPY immunoreactive neurons) in the hippocam-
pus of the APP/PS1 mice (Ramos et al., 2006; Baglietto-Vargas
et al., 2010; Takahashi et al., 2010). Therefore, changes in the
hippocampal inhibitory systems could explain the cognitive dys-
function in early stages of AD, but it is not clear whether is a
consequence of functional decline in GABAergic neurotransmis-
sion, speciﬁc interneuron degeneration, or an imbalance in the
excitatory/inhibitory activity, or a compound of these factors. Dif-
ferences in the methodological approach (i.e., neuronal recording,
genetically modiﬁed animal models, data analysis or in vitro vs.
in vivo studies) may explain these paradoxical results. On the
other hand, no clinical trial on GABAA receptor antagonists in
AD or MCI has been successful or even performed, and therefore
new studies are necessary in order to provide a link between basic
science and clinical applications.
In summary, since septohippocampal GABAergic projections
as well as intrahippocampal inhibitory interneurons have a main
role in hippocampal oscillatory activity, inhibitory neurotransmis-
sion is an excellent candidate to be affected by Aβ in AD.
Aβ AND GABAB RECEPTORS
Despite the existence and widespread distribution of the GABA
metabotropic type receptors (GABAB) in the central nervous
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system (Emson, 2007), their association with Aβ-induced pathol-
ogy in AD have not been examined deeply yet. GABAB are
coupled to intracellular signal transduction mechanisms via G
proteins (Mott and Lewis, 1994; Kaupmann et al., 1998). These
channels mediate slow and prolonged synaptic inhibition mainly
by postsynaptic G protein-coupled activated inwardly rectify-
ing potassium (GirK) channels (Luscher et al., 1997; Kaupmann
et al., 1998). At presynaptic level, GABAB receptors also mod-
ulate (rather than generate) rhythmic activity in the MS–DBB
(Henderson and Jones, 2005) and therefore have a possible role
on memory function. GABAB receptor-mediated inhibition reg-
ulates the slow oscillation during gamma and theta oscillations
in the control of cortical network activity (Kohl and Paulsen,
2010). Gamma oscillations have been associated with sensory
processing (Singer, 1993), memory (Fell et al., 2001; Sederberg
et al., 2007), attention (Fries et al., 2001), and ﬁnally, with con-
sciousness (Llinas et al., 1998). GABAA and GABAB receptors
are essential to learning and memory processes (Lasarge et al.,
2009; Heinrichs et al., 2010; Mizoguchi and Yamada, 2011) and
their pharmacological modulation affect the cognitive function.
Since redistribution of hippocampus-dependent memories to
neocortical sites is depending on slow oscillations (Diekelmann
and Born, 2010), is plausible a role of GABAB receptors on
this cognitive functions (Kohl and Paulsen, 2010). Autoradio-
graphy studies of hippocampus and cortex of postmortem AD
brains (Chu et al., 1987; Young, 1987) have shown a signiﬁcant
reduction of GABAB receptors. In the same way, up-regulation
of a novel non-coding RNA named 17A, RNA polymerase III-
dependent embedded in the human G-protein-coupled receptor
51 gene (GPR51, GABAB2 receptor), affect GABAB2 intracel-
lular signaling and enhances the secretion of Aβ (Massone
et al., 2011). Therefore, the association between GABAB recep-
tor dysfunction and Aβ-pathological metabolism is credible in
AD.
On the other hand, the expression of GABAB receptors sub-
units may differ in accordance with the progression of AD. An
immunohistochemical study in AD hippocampus demonstrated
that in early stages of neuroﬁbrillary tangle pathology the GABAB
receptor subunit R1 expression could be stable or increased, and
then decrease as the disease progresses (Iwakiri et al., 2005). These
changes indicate that compensatory mechanisms are limited and
the dysfunction of hippocampal inhibitory circuitry could involve
GABAB receptors.
From a therapeutic point of view, some studies suggest that
GABAB antagonists are more likely to have neuroprotective effects
than agonists (Lafon-Cazal et al., 1999; Bowery, 2006). In fact,
GABAB receptor antagonist may increase the expression of both
neurotrophins nerve growth factor (NGF) and brain-derived neu-
rotrophic factor (BDNF) in rat hippocampus (Heese et al., 2000).
Similarly, GABAB receptor agonist failed to inhibit Aβ-induced
neuronal death (Lee et al., 2005; Marcade et al., 2008), while
GABAB antagonist may improve cognitive performance in several
animal models (Farr et al., 2000; Genkova-Papazova et al., 2000).
NewGABAB receptor antagonists have been developed for numer-
ous in vitro and in vivo studies (Froestl, 2010). However, there is
no clear evidence for its application in AD or any other cognitive
dysfunction. Finally, high doses of GABAB receptor antagonists
as well as GABAB receptor knock-out interrupt hippocampal and
cortical oscillations leading to epileptiform activity and sponta-
neous seizures, respectively (Vergnes et al., 1997; Prosser et al.,
2001; Schuler et al., 2001; Leung et al., 2005). In this sense, GABAB
receptors modulation must have an important function in order
to reach both, an effective neuroprotection and avoid epileptiform
activity.
Aβ AND GirK CHANNELS
GABAB receptors andGirK channels are coupled and co-expressed
in the postsynaptic membrane of pyramidal neurons in the hip-
pocampus (Luscher et al., 1997; Kulik et al., 2003; Lujan et al.,
2009) conforming an oligomeric stable molecular complex (Lujan
et al., 2009; Ciruela et al., 2010). GirK channels act as key players
in the control of cellular and network excitability by modulating
synaptic activity in brain structures which participate in cogni-
tive functions (Ciruela et al., 2010). GirK channels exhibit a tonic
basal activity, even without receptor signaling, due to their direct
binding to the Ga subunit of G proteins (Lujan et al., 2009).
Therefore, it is plausible an Aβ-induced intracellular signaling
impairment which compromises this effector system. In fact, Aβ
has been shown to disrupt G protein-coupled receptors func-
tion (Thathiah and De, 2011), and compromise coupling of the
receptor with G protein (Janickova et al., 2013) as well as several
different secondary messenger systems (Thathiah and De, 2009;
Yang et al., 2011; Fu et al., 2012; Zhang et al., 2014). In addition,
we have recently showed that Aβ decrease GABAB currents in CA3
pyramidal neurons, a putative mechanism of Aβ-induced synap-
tic dysfunction observed in the septohippocampal system, which
likely occur directly on GirK channels (Nava-Mesa et al., 2013).
GirK channels activity alteration may have multiple impli-
cations for synaptic activity, neuronal network function and
cognitive processes. Numerous studies have emphasized its role
in several pathological processes in the central nervous system
such as epilepsy, pain, addiction, Parkinson or Down syndrome
(Luscher and Slesinger, 2010). Deletion studies have revealed GirK
channels role in learning and memory processes. GIRK4 knock-
out mice exhibited impaired performance in a spatial learning
and memory task (Wickman et al., 2000). Moreover, mutations
in GIRK2 subunit reduced LTP and increased LTD in hippocam-
pus (Sago et al., 1998; Siarey et al., 1999; Wickman et al., 2000)
and it is especially relevant in Down syndrome, where cerebral
Aβ accumulation is greatly accelerated and leads to invariant
early onset AD neuropathology as well as learning and mem-
ory impairment (Lott and Head, 2005; Moncaster et al., 2010;
Cooper et al., 2012).
Since loss-of-function of GirK channels might take part in the
mechanisms that lead to excessive neural excitability and epilepsy
that can be observed in hAPP transgenic mice model (Palop et al.,
2007; Palop and Mucke, 2009, 2010a,b; Mucke and Selkoe, 2012),
this type of potassium channels emerge as an interesting potential
target to be studied, particularly now that its crystal structure has
just been resolved (Whorton and MacKinnon, 2011).
GirK channels may be activated in a G protein-independent
manner by different compounds (Kobayashi et al., 1999; Lewohl
et al., 1999; Yamakura et al., 2001; Yow et al., 2011) and are blocked
by different types of antidepressants (Kobayashi et al., 1999).
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However, there is little evidence for GirK subtype-speciﬁcity or
pharmacokinetic advantages of most of those compounds, as
they have other primary molecular targets (Lujan et al., 2013).
However, a new class of subtype-selective agonists and antago-
nists has been identiﬁed (Kaufmann et al., 2013; Ramos-Hunter
et al., 2013; Wen et al., 2013). An example is ML297, which has
been found to be a potent, effective, and selective activator of
GirK channels via a Gi/o-coupled receptor with preference for
GIRK1/GIRK2 subunit combination (Days et al., 2010). This drug
displays antiepileptic properties in animals models (Kaufmann
et al., 2013) and might have a possible therapeutic potential for
MCIorAD.As already discussed, seizures and epileptiformactivity
inAD subjects support the hypothesis that aberrant network activ-
ity contributes causally to synaptic and cognitive deﬁcits (Palop
and Mucke, 2009). Thus antiepileptic drugs (i.e., levetiracetam)
might ameliorate those deﬁcits (Sanchez et al., 2012; Vossel et al.,
2013).
In summary, tonic GirK channel activity is necessary to con-
trol neuronal excitability and synaptic function. Therefore, GirK
channels emerge as an interesting potential target to understand
the physiopathology of the early stages of AD. A new class of selec-
tive GirK agonists with antiepileptic properties appears as a novel
therapeutic tool to be tested in further studies.
FUTURE CLINICAL DIRECTIONS
The currently available therapy for AD (memantine, acetyl-
cholinesterase inhibitors) may slow the progression of symptoms,
but there are no existing treatments that reverse or stop disease
progression even though the multiple advances in clinical and
basic research.
As mentioned previously, GABAA receptor agonists have
shown neuroprotective effects against Aβ-induced neurotoxicity
in animal and in vitro models. Tramiprosate is an anti-amyloid
compound for the treatment of AD. This drug has shown to
reverseAβ-induced synaptic plasticity dysfunction through activa-
tion of GABAA receptors (Aisen et al., 2006; Gervais et al., 2007).
A phase III clinical trial showed a signiﬁcant reduction in the
hippocampus volume loss, but non-signiﬁcant reduction in cogni-
tive impairment (Aisen et al., 2011). Apparent divergence between
neuroimaging lesions and cognitive deﬁcitsmake difﬁcult to deter-
mine reliable markers of AD. Other type of GABAA agonist (i.e.,
benzodiazepines) may have a signiﬁcant role to manage psycho-
logical symptoms associated with AD. However, the undesirable
side-effects associated and plausible receptor desensitization limit
their chronic use (Lanctot et al., 2007). Furthermore, cognitive
declinewith lorazepam in individuals with higher risk forAD (car-
riers of APOE-epsilon4 allele, a common AD susceptibility gene)
has been reported in a double-blind crossover study (Stonnington
et al., 2009).
On the other hand, GABAB receptor is involved in the phys-
iopathology of AD, and then is a pharmacological potential target.
In a phase II trial, the GABAB receptor antagonist SGS742
improved cognition and memory performance in MCI possi-
bly by up-regulation of GABAB receptors (Froestl, 2010) or
through speciﬁc hippocampal protein expression (Sunyer et al.,
2008; John et al., 2009). Nevertheless, in a more extensive
phase IIb clinical trial in subjects with mild to moderate AD
(http://www.clinicaltrials.gov/ct2/show/NCT00093951), the same
drug was unsuccessful (Sabbagh, 2009).
Cumulative evidence indicates that the imbalance between exci-
tatory and inhibitory neurotransmitter systems may underline the
early cognitive deﬁcits in AD. In this sense, antiepileptic drugs
(i.e., levetiracetam and topiramate) may reverse the synaptic dys-
function associated with learning and memory impairment in
animal models (Sanchez et al., 2012; Shi et al., 2013). A retro-
spective observational study, patients with amnestic MCI or early
AD, treatment with lamotrigine and levetiracetam has shown clin-
ical beneﬁts and good tolerability (Vossel et al., 2013). In contrast,
chronic treatment with valproate was associated with signiﬁcant
toxic effects including morphological brain changes in patients
with moderate AD (Tariot et al., 2011).
Several clinical studies, including meta-analysis and clinical
trials (Wei et al., 2007; Alvarez et al., 2011; Allegri and Guekht,
2012) reported the cognitive beneﬁts of a mixture of neurotrophic
factors (i.e., the nootropic agent cerebrolysin) as a therapeutical
alternative for AD. In fact, those neurotrophic peptides can act as
a neuroprotective agent or by synergically enhancing the effects
of cholinesterase inhibitors (Alvarez et al., 2011). Finally, cere-
brolysin may also regulate synaptic activity via presynaptic GABAB
receptors on hippocampus (Xiong et al., 1996) and it also could
improve cognitive performance in patients with mild to moderate
AD according to several clinical trials (Wei et al., 2007).
In conclusion, since cholinergic or glutamatergic treatments in
AD have shown limited success, therapies combining modulators
of different neurotransmission systems seem to be a more useful
tool for the treatment, and overall prevention, of this demen-
tia. Pharmacological strategies to recover the unbalance between
excitatory and inhibitory neurotransmitters have to take into
account the GABAergic system. In this sense, recent data suggest
that GABAB activity modulators which may control the neuronal
excitability, as well as neurotrophic factors, are very interesting
targets to be considered for further studies.
CONCLUDING REMARKS
It is reasonable to consider that Aβ-induced pathology on
inhibitory synaptic activitymight be explainedby both their effects
on speciﬁc inhibitory circuits or indirect effects on excitatory affer-
ents to GABA neurons (Figure 1). Because of the availability of
Aβ on synaptic cleft and the particular vulnerability of each neu-
ronal circuit, some Aβ effects depend on the brain structure under
study. On the other hand, there is increasing evidence to suggest
that GABAergic neurons are relative spared in animal models of
AD-like amyloid pathology. However, Aβ modulates inhibitory
GABA activity through functional compensatory up-regulation
mechanismsor neurodegenerationon cholinergic and glutamater-
gic neurons, which in turn innervate GABA interneurons. So
GABAergic neurons are responsible for brain rhythmic activity
necessary for learning and memory processing. It is necessary to
note that many of the differences between studies are related to the
experimental model used. The Aβ peptide fraction and also the
exposure time or differences between acute, sub-acute and chron-
ically models should be highlighted. In this manner, the effects of
Aβ in the short-term tend to be more functional than structural
while in the long or chronic –term effects induce activation of
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FIGURE 1 | Mechanisms of synaptic dysfunction in Alzheimer’s disease.
Schematic drawing showing the role of Aβ in the physiopathology of AD and
different targets for pharmacological modulation. AD is explained by
Aβ-induced neurodegeneration, therefore with decline in synaptic terminals
(left) on both principal cells and inhibitory interneurons. Chronic exposition to
Aβ induces neuronal death. Synaptic loss is related with cognitive impairment
in AD. Early memory decline is correlated with Aβ-synaptic dysfunction on
excitatory and inhibitory receptors and neurotransmission. Current evidence
for the treatment of AD involve both glutamatergic (NMDA-type glutamate
receptors antagonist, i.e., memantine) and cholinergic (i.e., cholinesterase
inhibitors, AChE inhibitors) transmission. The GABAergic system is a possible
target for developing pharmacological interventions. GABAB receptors may
be blocked by Aβ. However, GABAB antagonists induce GABAB receptors
up-regulation and neurotrophic factors expression. GABAA modulation (i.e.,
by GABAA receptor agonist and selective inverse agonist) may have nootropic
and neuroprotective effects. Although GABA interneurons are spared in
several AD models, the imbalance between excitatory and inhibitory
neurotransmission might underlie early AD cognitive dysfunction.
Abbreviations: Aβ, Amyloid-β; AchR, acetylcholine receptor; AChE,
acetyl-cholinesterase; α7-nAChR, α7-nicotinic acetylcholine receptor; BDNF,
brain-derived neurotrophic factor; GirK, G protein-gated inwardly rectifying
potassium channel; KCNQ, Kv7 family of voltage-gated potassium channels;
LTP, long-term potentiation; LTD, long-term depression; NGF, nerve growth
factor.
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compensatory mechanisms that possibly involve increased expres-
sion of speciﬁc receptors subunits, which would be interesting
molecular targets for drug development.
Hence, new therapeutical approaches must take into account
the different drug’s action mechanisms, diverse neurotransmitters
systems involved and ﬁnally, selective different cell targets in order
to produce a better clinical results.
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